Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer

Table 1 Relationship between clinicopathological characteristics and prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients

Clinicopathological characteristics	All patients (n = 176)		5-yr OS (%)	P value
	n	%
Sex
Male	131	74.4%	17.4%	0.702
Female	45	25.6%	15.8%
Age (yr)
≥ 60	68	38.6%	21.8%	0.799
< 60	108	61.4%	13.5%
Tumor location
Upper third	43	24.4%	17.7%	0.614
Middle third	56	31.8%	19.6%
Lower third	62	35.2%	19.6%
Total	15	8.5%	0.0%
Tumor grade (differentiation)
Moderate	15	8.5%	19.3%	0.241
Poor	161	91.5%	16.5%
Lymphovascular invasion
Yes	139	79.0%	10.3%	0.010
No	37	21.0%	30.6%
No. of positive LNs
0	4	2.3%	37.5%	0.174
1-6	17	9.7%	31.2%
7-15	10	5.7%	0.0%
≥ 16	145	82.4%	15.8%
No. of dissected LNs
≥ 30	106	60.2%	20.6%	0.326
< 30	70	39.8%	11.6%
Positive LN ratio
≥ 0.8	34	19.3%	6.2%	0.048
< 0.8	142	80.7%	20.5%
Pathologic T stage1
T2	5	2.8%	40.0%	0.420
T3	20	11.4%	30.6%
T4a	102	58.0%	12.6%
T4b	49	27.8%	21.2%
Stage1
IIIA	5	2.8%	40.0%	0.237
IIIB	15	8.5%	35.9%
IIIC	156	88.6%	14.0%

¹Recorded based on the American Joint Committee on Cancer (AJCC) TNM Staging Classification for Carcinoma of the Stomach (7^th edition, 2010). LN: Lymph node; OS: Overall survival.

Table 2 Multivariate analysis of the prognostic factors for overall survival of T4bN1-3M0/TxN3bM0 gastric cancer patients

Clinicopathological characteristics	P value	Odds ratio	95%CI
			Lower	Upper
Lymphovascular invasion	0.01	1.80	1.15	2.8
Node positive rate	0.14	1.36	0.90	2.1
Stage	0.49	0.71	0.34	1.5

LN: Lymph node.

Table 3 Overall survival according to patterns of recurrence in T4bN1-3M0/TxN3bM0 gastric cancer patients after curative resection

Recurrent sites	Recurrent patients (n = 147)		Median OS (mo)	5-yr OS(%)	P value
	n	%
Locoregional	33	22.5%	33.9	28.0%	0.001
Peritoneal	38	25.9%	16.0	0.0%
Distant	67	45.6%	21.3	14.7%

Table 4 Overall survival of patients with T4bN1-3M0/TxN3bM0 gastric cancer according to distant site of metastasis

Distant metastasis site	Recurrent patients (n = 147)		Median OS (mo)	5-yr OS(%)
	n	%
Liver	26	17.7%	18.3	15.5%
Lung and pleura	12	8.2%	16.8	0.0%
Bone	10	6.8%	30.7	29.2%

Table 5 Relationship between adjuvant treatment and the prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients

Treatment		n	Median DFS (mo)	3-yr DFS (%)	P value	MedianOS (mo)	5-yr OS (%)	P value
Adjuvant chemotherapy	Yes	164	12.3	10.4%	0.000	25.7	16.1%	0.532
	No	12	2.8	0.0%		18.7	22.2%
Chemotherapy	Mono- therapy	10	6.7	0.0%	0.583	20.3	0.0%	0.661
Regimen	Doublet	134	12.0	5.3%		26.3	17.4%
	Triple	20	13.0	5.3%		29.7	18.5%
Adjuvant chemotherapy time	≥ 6 mo	39	23.2	20.2%	0.000	40.2	25.0%	0.001
	< 6 mo	125	9.9	7.3%		21.6	13.4%

DFS: Disease-free survival.